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GW627368X inhibits proliferation and induces
apoptosis in cervical cancer by interfering with
EP4/EGFR interactive signaling
S Parida1, I Pal1, A Parekh1, B Thakur2, R Bharti1, S Das2 and M Mandal*,1
PGE2, the major product of cyclooxygenases implicated in carcinogenesis, is significantly upregulated in cervical cancer. PGE2
via prostanoid receptor EP4 stimulates proliferation and motility while inhibiting apoptosis and immune surveillance. It promotes
angiogenesis by stimulating the production of pro-angiogenic factors. The present study demonstrates GW627368X, a highly
selective competitive EP4 antagonist, which hinders cervical cancer progression by inhibiting EP4/epithelial growth factor
receptor (EGFR) interactive signaling. GW627368X reduced protein kinase A (PKA) phosphorylation which in turn leads to
decreased cAMP response element-binding protein (CREB) activation. Decreased PKA phosphorylation also directly enhanced
Bax activity and in part reduced glycogen synthase kinase 3 (GSK3)β phosphorylation. Owing to the interactive signaling between
EP4 and EGFR, GW627368X lowered EGFR phosphorylation in turn reducing Akt, mitogen-activated protein kinase (MAPK) and
GSK3β activity significantly. Sublethal dose of GW627368X was found to reduce the nuclear translocation of β-catenin in a time
dependent manner along with time-dependent decrease in cytoplasmic as well as whole-cell β-catenin. Decreased CREB and
β-catenin transcriptional activity restricts the aberrant transcription of key genes like EP4, cyclooxygenase (COX)-2, vascular
endothelial growth factor and c-myc, which ultimately control cell survival, proliferation and angiogenesis. Reduced activity of
EGFR resulted in enhanced expression of 15-hydroxyprostaglandin dehydrogenase increasing PGE2 degradation thereby
blocking a positive feedback loop. In xenograft model, dose-dependent decrease in cancer proliferation was observed
characterized by reduction in tumor mass and volume and a marked decrease in Ki67 expression. A diminished CD31 specific
staining signified decreased tumor angiogenesis. Reduced expression of pAkt, pMAPK, pEGFR and COX-2 validated in vitro
results. GW627368X therefore effectively inhibits tumor survival, motility, proliferation and angiogenesis by blocking EP4/EGFR
interactive signaling. EP4 is a potent therapeutic target in cervical cancer and can be explored in combination with conventional
therapies to attain superior outcomes and to overcome complications associated with organ toxicities, therapeutic resistance and
disease relapse.
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Cervical cancer is the second most common cancer affecting
womenworldwide and secondmost common killer of women in
developing nations accounting 86% of cervical cancer deaths.
In India, 122 844 women are diagnosed with cervical cancer
annually and 67 477 die from the disease.1 In US, 12 900
cases and 4100 deaths are expected in 2015. Despite a
declining trend, incidence and mortality has normalized in the
past decade even in developed nations.2 Despite recent
advances in chemo and radiotherapy, treatment failure and
disease relapse remain to be major problems. Currently
available prophylactic vaccines against a subset of HR-HPVs
hold promise for reducing burden in future generations.
However, these vaccines do not protect women already
inflicted with the infection. Efforts for developing therapeutic
vaccines against viral antigens E6 and E7 are underway and
despite being able to induce viral antigen specific cytotoxic
T cells in human, they have proven largely ineffective in treating
HPV-induced cervical cancer.3 The vaccines are yet to be
approved in many countries and mass vaccination in develop-
ing countries is difficult due to lack of infrastructure and other
socioeconomic factors. Development of newer and more
effective therapeutic agents therefore remains indispensable.
COX-2 upregulation and enhanced PGE2 synthesis in
cervical carcinoma is well known and it regulates neoplastic
cell function via the EP2 and EP4 receptors.4 COX-2 expres-
sion is correlated with higher vascular endothelial growth factor
(VEGF) expression, lymphangiogenesis and lymph node
metastasis in cervical cancer.5 Most of the effects of COX-2
are attributed to its enzymatic product PGE2.6 However,
another isoform of the enzyme, COX-1, earlier considered to
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have housekeeping roles, is found to be overexpressed in
cervical cancer consistent with COX-2 and PGE2.7 Studies
suggest that COX-1 upregulation modulates the expression of
COX-2, PGE2 receptors and angiogenic factors in cervical
cancer.7 PGE2 stimulates cell proliferation and motility while
hindering immune surveillance and preventing apoptosis.8
PGE2 stimulates angiogenesis by stimulating the synthesis of
pro-anigiogenic factors including VEGF. Stimulation of EP4 by
PGE2 also activates TCF-β-catenin-mediated transcription that
in turn leads to increased expression of variety of genes
implicated in cancer-like cyclin D1 and c-myc.8 Moreover,
PGE2 has distinct organ specific effects as it is associated with
estrogen biosynthesis. Estrogen biosynthesis is catalysed by
aromatase, product of CYP19 gene. Binding of PGE2 to EP4
receptor stimulates adenylyl cyclase activity enhancing cyclic
adenosine monophosphate production which induces the
transcription of gene encoding aromatase via CREB.8 Conse-
quently there is increased biosynthesis of aromatase enzyme. It
is important mediator in cervical carcinogenesis as the uterine
cervix is highly responsive to estrogen. Recently it has been
reported that estrogen and its nuclear receptors promote
cervical cancer in combination with HPV.3 Estrogen is also
known to be independently capable of inducing cervical
epithelial hyperplasia.3
Folds (106) higher expression of EP4 is reported in cervical
cancer compared with normal controls.4 Moreover, EP4, unlike
other prostanoid receptors, associates with multiple signaling
pathways involved in carcinogenesis.9 In the present study we
demonstrate EP4 prostanoid receptor as a potential therapeu-
tic target in cervical cancer using GW627368X, a highly
selective, competitive EP4 antagonist.10 We explored the
interactive signaling between EP4 prostanoid receptor and the
epidermal growth factor receptor (EGFR). GPCRs and EGFR
are known to be simultaneously overexpressed and contribute
to aberrant proliferation of cancer by activating autocrine
pathways.11 PGE2 can stimulate EGFR in many complex and
context specific mechanisms.11 PGE2, via the EP4 receptor,
stimulates cyclic AMP-protein kinase A (PKA) pathway which
increases expression of EGFR ligand amphiregulin.8 EGFR
transregulation by PGE2 is also known to be mediated by
intracellular Src-dependent mechanism independent of extra-
cellular EGFR ligands.8 PGE2 stimulates matrix metallopro-
teinase activity resulting in the shedding of active EGFR
ligands from the plasma membrane, which in turn magnifies
EGFR signaling and enhances DNA synthesis in certain
cancers.11 On the other hand, activation of EGFR signaling
leads to increase inMAPK activity resulting in activator protein-
1-mediated induction of COX-2 transcription and enhanced
synthesis of PGE2.8,11,12 Stimulation of EGFR signaling also
inhibits expression of 15-hydroxyprostaglandin dehydrogen-
ase, the key enzyme for catabolism of PGE2, leading to
enhanced accumulation of PGE2 in the tumor vicinity due to
increased production and decreased degradation.
Results
GW627368X inhibits the proliferation of cervical cancer
cells in time and dose-dependent manner by inducing
apoptosis. The potential of GW627368X to inhibit
proliferation of cervical cancer cell lines was evaluated by
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
(MTT) assay. The IC50 values for HeLa, SiHa and ME 180 cell
lines were found to be 17.44±0.88, 29.92±0.83 and
23.22±0.95 μM, respectively, at 24 h and 9.082± 0.8,
11.3±0.91 and 11.16±0.94 μM, respectively, at 48 h
(Figure 1a). A similar time-dependent decrease in cell viability
was also observed from live/dead assay (47.39±5.992,
50.06±4.894 and 43.45±5.417% in HeLa, SiHa and ME
180, respectively, after 48 h; Figures 1c and d). Minimal
cytotoxicity was observed in case of normal cells evident from
IC50, 110.5±0.84 μM, 488.2± 0.8 μM and 171.9±0.872 μM
for HaCat, NIH/3T3 and HBL-100, respectively (Figure 1a). To
further study the chronology of cellular events after
GW627368X treatment, cell cycle analysis was performed
by flow cytometry with treatment slightly lower than IC50 value
(9, 10 and 10 μM for HeLa, SiHa and ME 180, respectively).
A time-dependent accumulation in sub G0/G1 phase was
observed. Percentage of sub G0/G1 population substantially
increased to 45.46± 2.1, 41.39±3.7 and 57.61±1.3 when
treated compared with 1.82±0.9, 1.83±0.7 and 3.81±0.3 in
control in HeLa, SiHa and ME 180, respectively (Figure 1b).
GW627368X inhibits growth in cervical cancer cells by
inducing apoptosis was indicated by morphological studies
using DAPI/Rhodamine phalloidin staining (Figure 2a). Typi-
cal changes in cell morphology including cell shrinkage,
disruption of actin filaments, nuclear fragmentation and
apoptososme formation was observed. Apoptotic cell death
was further confirmed by a time-dependent increase in
terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL)-positive green nuclei (Figure 2b). Activation of pro-
caspase 3 is important for induction of apoptosis further
leading to increased PARP cleavage. A time-dependent
decrease in cellular levels of pro-caspase 3 and increase in
levels of cleaved PARP was observed in all cell lines
(Figures 2c and d). The PGE2/EP4 pathway is known to
suppress apoptosis in cervical cancer cells by preventing the
translocation of pro-apoptotic protein BAX into the mitochon-
dria. Time-dependent expression levels of pro-apoptotic
proteins BAX and apoptosis-inducing factor were studied
following drug treatment by western blot analysis and showed
a significant increasing pattern. Further a decrease in levels
of anti-apoptotic proteins, Bcl-2, Bcl-xl and XIAP was
observed in a time-dependent manner in all the cell lines
(Figures 2c and d). These findings could be correlated with
the results of MTT as well as TUNEL and Live/Dead assays.
GW627368X impedes migration and invasion of cervical
cancer cells. Potential of GW627368X to impede migration
and invasion of cervical cancer cells was determined from
wound healing and Boyden chamber assays. Considerable
wound closure was observed in control cells after 48 h
(2.5± 0.2887, 3.033± 0.0819 and 4.033± 0.1453 μm, N= 3
in HeLa, SiHa and ME 180, respectively). However, little
healing was observed in drug treated groups (7.140±0.2358,
6.667±0.3283 and 7.2± 0.15281453 μm, N= 3 in HeLa,
SiHa and ME 180, respectively; Figures 3a and b). Boyden
chamber assay revealed about 30% reduction (P=0.0002) in
invasive potential of ME 180 cells, most invasive of all the cell
lines (Figures 3c and d).
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GW627368X inhibits angiogenesis, an important phe-
nomenon in carcinogenesis. Angiogenesis, an indispen-
sable phenomenon in tumor progression, is regulated by
numerous angiogenic factors; the most important one being
VEGF. Numerous studies have indicated that the role of
prostaglandin E2 (PGE2) and VEGF are closely intertwined
in regulation of tumor angiogenesis. PGE2 has been reported
to promote angiogenesis independently as well as by
stimulating the production of VEGF. In addition, reports also
suggest that effect of VEGF on angiogenesis, at least in part,
is mediated by PEG2 synthesis. An increased PGE2
signaling via EP4 receptor is known to activate a positive
feedback loop thus enhancing COX-2, PGE2, EP4 and VEGF
expression further amplifying angiogenic response.5 There-
fore, GW627368X, an EP4 receptor inhibitor, was hypothe-
sized to have anti-angiogenic potential. To determine anti-
angiogenic properties of GW627368X, levels of PGE2 and
VEGF in conditioned medium was quantified by enzyme-
linked immunosorbent assay (ELISA). Significant decrease in
levels of PGE2 on treatment was observed in all cell lines.
PGE2 levels significantly rose on stimulation with 10 μM
arachidonic acid (700.4±6.104, 802.9±8.395, 798.6±
19.01 pg/ml,N= 3) compared with control (500.8± 9.616,
500.6±12.07, 618.0± 18.51 pg/ml, N= 3) in HeLa, SiHa
and ME 180, respectively (Figure 4c). However, comparable
decrease in PGE2 levels in conditioned medium was
observed in both stimulated (493.4± 20.31, 583.5±12.58,
608.1±2.915 pg/ml, N= 3 for HeLa, SiHa and ME 180,
respectively) and unstimulated cells (294.2± 6.807,
225.5±7.945, 281.4± 12.13 pg/ml, N= 3 for HeLa, SiHa
and ME 180, respectively; Figure 4b). Consequently,
decrease in secretory VEGF was observed in all cell lines
when treated with GW627368X (135.5±4.16, 163.5±9.034,
300.0±11.36 pg/ml, N= 3 for Hela, SiHa, ME 180, respec-
tively) compared with untreated control (634.6± 29.92,
454.4±8.695, 701.4± 24.12, N=3 Hela, SiHa, ME 180,
respectively; Figure 4d). Further, expression profiles of
COX-2, EP4, p-vascular endothelial growth factor receptor
and HIF1α at different time periods of drug treatment was
inspected by western blot analysis. Time-dependent
decrease in expression level was observed in each protein
(Figures 4a and b). Anti-angiogenic potential of GW627368X
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Figure 1 Anti-proliferative potential of GW627368X. (a) Dose-dependent inhibitory effect of GW627368X on growth of cervical cancer cell lines. Cervical cancer cell lines
HeLa, SiHa, ME 180 and normal cell lines NIH/3T3, HaCat and HBL-100 were treated with various concentrations of GW627368X for 24 and 48 h. Points, average± S.D.,
representative of three independent experiments each performed in triplicates, Po0.05. (b) Cell cycle analysis. Indicated cell lines were treated slightly lower than IC50 (48 h)
dose of the drug (9, 10 and 10 μM for Hela, SiHa and ME 180, respectively) in treatment groups and 0.1% DMSO in control for indicated time periods. (c and d) Live dead assay.
(c) Micrographs representing cells stained with Calcein AM and Ethidium bromide homodimer after treating the cells for indicated time periods. Viable cell population appears
green (calcein AM) whereas non-viable/dead cells appear as orange/red (ethidium bromide) in the fluorescent micrographs. (d) Graphical representation of percentages of live
and dead cells represented as histogram, Values presented as mean± S.D.; *Po0.05, **Po0.01, ***Po0.001
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was analyzed in vitro by tube formation assay. The number of
tube like capillaries formed by HUVECs significantly con-
strained when treated with the drug (Figures 4e and f). These
in vitro results were further validated in vivo by chorioallantoic
membrane assay. VEGF treatment increased number of
small blood vessels in developing chick embryo compared
with control, however, an avascular zone was observed
around the area of drug treatment in the third group
(Figures 4g and h). The number of capillaries were counted
and plotted.
GW627368X inhibits proliferation and induces apoptosis
in cervical cancer cells via multiple pathways involving
EP4/PKA/CREB, EGFR/Akt/GSK3β/β-catenin and
EGFR/Ras/MAPK/CREB. EP4 receptors blockade with
GW627368X resulted in significant reduction in proliferative
potential and induced time and dose-dependent apoptosis in
cervical cancer cells. To trace the cellular pathways affected
by GW627368X, cells were stimulated with EGF and
phosphorylation status of downstream effectors was studied
by western blot. EP4 has been previously reported to be
Figure 2 GW627368X induces apoptosis in cervical cancer cells HeLa, SiHa and ME 180 in time-dependent manner. Cells treated with 9, 10 and 10 μM GW627368X for
Hela, SiHa and ME 180, respectively, for indicated time periods, (a) stained with Rhodamine phalladoin and counter stained with DAPI and images captured at × 20 magnification.
Nuclear fragmentation and disruption of actin cytoskeleton, characteristic of apoptotic cell death, was observed (b) TUNEL assay was performed and fluorescent images were
captured. Time-dependent increase in TUNEL-positive green nuclei indicated induction of apoptosis, (c and d) Western blot analysis of apoptotic proteins, (c) Blots depicting
expression profile of apoptotic and anti-apoptotic proteins in cervical cancer cells treated with GW627368X for indicated time periods compared with control treated with 0.1%
DMSO, β-actin used as loading control (d) Quantification of protein expression by densitometry, normalized to β-actin, each representative of three different experiments each
performed in triplicates, values presented as mean± S.D.; *Po0.05, **Po0.01, ***Po0.001
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coupled with PKA or adenylyl cyclase, thus elevating
intracellular cyclic AMP levels ultimately leading to increased
phosphorylation of CREB transcription factor which further
augments the transcription of multiple genes.13 Interestingly,
in our study along with decreased PKA and CREB phosphor-
ylation, we observed a significant downregulation of EGFR
phosphorylation (Figures 5a–d). Further, on western blot
analysis we observed a time-dependent decrease in β-catenin
expression with respect to control cells (Figures 5e-g). These
findings opened up the possibility of cross talk between EP4/
CREB and EP4/EGFR pathways. On detailed analysis we
found that treatment with GW627368X significantly reduced
phosphorylation levels of EGFR, Ras, Akt, GSK3β and MAPK
in both stimulated and unstimulated cells while levels of total
proteins remained unchanged (Figures 5a–d). On treating the
cells with a sub-lethal dose of the drug (one-third of IC50), a
time-dependent decrease in expression of β-catenin in SiHa
and ME 180 cells along with decreased nuclear accumulation
was found (Figures 5e–g). Our results thus indicated that
GW627368X hindered proliferation and induced apoptosis in
cervical cancer cells via the cyclic adenosine monopho-
sphate/PKA/CREB as well as pathway involving EGFR/Ras/
MAPK/CRB and Akt/GSK3β/ β-catenin. Reduced PKA
phosphorylation also stimulated Bax-induced apoptosis.
Decreased activity of CREB and β-catenin can be implicated
in reduced levels of VEGF, COX-2 and PGE2.
To further validate our hypothesis that GW627368X hinders
cervical carcinogenesis via EP4/EGFR interactive signaling,
we studied the phosphorylation status of key effector
molecules after exogenously over-expressing PGE2. On
stimulating the cells with PGE2, a highly significant amplifica-
tion of pEGFR was observed while the total EGFR levels
remained unaffected (Figures 6a and b). It markedly reduced
post GW627368X treatment in both stimulated and unstimu-
lated cells (Figures 6a and b). An increase in ambient PGE2
resulted in increased CREB phosphorylation as well as
increase in pMAPK, pAkt and pGSK3β (Figures 6c–h).
GW627368X being a competitive EP4 antagonist prevented
Figure 3 GW627368X impedes migration and invasion of cervical cancer cells. (a and b) Wound healing assay. Cells were allowed to grow in monolayers in six-well plates
and the monolayer was wounded with a pipette tip. Cells were then treated with one third IC50 of GW627368X. The control cells were treated with 0.1% DMSO. (a) The wounds
were observed and photographed till 48 h at regular intervals. (b) Graphical representation of wound size at different time points. (c and d) Boyden chamber assay.
(c) Micrographs representing invasion of HeLa, SiHa and ME 180 cells following treatment with GW627368X. (d) Graph depicting percentage of cells invading the inserts of Boyden
chamber coated with matrigel, representative of three different experiments each performed in triplicates, values presented as mean±S.D.; *Po0.05, **Po0.01, ***Po0.001
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binding of PGE2 to its receptor bringing down the levels
pMAPK, pAkt, pGSK3β and pCREB (Figures 6c–h). Interest-
ingly, we observed a similar downregulation of pAkt, pGSK3β,
pMAPK and relatively lower, but significant downregulation of
pCREB on blockade of EGFRusingmAbwithout GW627368X
(Figures 6c–h). Activation of these effectors was further
reduced on simultaneous blockade of both EP4 and EGFR
(Figures 6c–h) suggesting a crosstalk of pathways being
affected. The results obtained above were validated by
comparing it with another highly selective EP4 receptor
inhibitor, CJ-023423 (Figure 7). The IC50 of CJ-023423 against
ME 180 was determined to be 7.611± 0.9416 μM for 48 h
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(Figure 7a). Phosphorylation studies were then performed
treating ME 180 cells with either 7 μM CJ-023423 or 10 μM
GW627368X (Figure 7b) and the results compared
(Figure 7c). A similar and slightly higher inhibition of EGFR,
Akt, PKA and MAPK phosphorylation was observed, validat-
ing our previous results.
GW627368X hinders tumor progression in vivo. The
effect of GW627368X on ME 180 and SiHa xenograft models
were studied by treating subcutaneous tumor-bearing nude
mice with oral dosage of the drug ranging from 0 to 10 mg/Kg
body weight, thrice a week, for 4 weeks. Significant reduction
in volume of tumors with increase in drug dose was observed
in both cases (P=0.0125, N=5 for ME 180 and P=0.0002,
N=5 for SiHa; Figure 8a). In ME 180 xenograft, final tumor
volume in highest treatment group reduced to
133.7±17.28 mm3 compared with 1348±53.63 mm3 in con-
trol group (Po0.0001, N=5; Figures 8b and c). Cervical
cancer cell line SiHa is known to form poorly differentiated
tumor in nude mice. Though a very similar regression in tumor
was observed, clear results could not be obtained in case
of SiHa xenograft because of very low initial tumor volume.
Final tumor volume in highest treatment group reduced
to 2.033±1.184 mm3 compared with 22.92±5.641 mm3 in
control group (P=0.023, N=5; Figures 8d and e). The weight
of the animals remained grossly similar from beginning to end
of treatment. All further staining and immunohistochemistry
(IHC) based studies were performed on tissue sections
obtained from ME 180 xenografts. Inhibition of proliferation
was evident from IHC specific to Ki67 indicating significantly
lower expression in treatment groups compared with control
(Figure 8f). DNA fragmentation within tumor tissue due to
apoptosis promoting effect of GW627368X was evident from
TUNEL assay (Figure 8f). Decrease in angiogenesis in vivo
was also evident from decreased intensity of CD31 staining in
treatment groups versus controls (Figure 8f). Expression
profiles of important components of signaling pathway by IHC.
A decreased expression of COX-2, pAkt, pMAPK and pEGFR
was observed in treatment groups whereas that of tAkt,
tMAPK and tEGFR differed slightly or remained unchanged
(Figure 8g). These results in vivo were consistent with results
obtained in vitro.
Discussion
In the present study, we demonstrated the potential therapeu-
tic efficacy of GW627368X in inhibiting cervical carcinogen-
esis in vitro and in vivo by hampering EP4-mediated multiple
signaling cascades. GW627368X is a potent, highly selective,
competitive EP4 prostanoid receptor antagonist with Ki value
of 100 nM.10 EP4 is known to be significantly upregulated in
cervical cancer consistent with overexpression of COX-1,
COX-2 and their product, PGE2.7,14–17 It has also been
associated with poor chemotherapeutic outcome and lymph
node metastasis in cervical cancer.5,7,18,19 In our study,
GW627368X was used as a selective blocker in three HPV-
positive cervical cancer cell lines, HeLa, SiHa and ME 180,
and was found to diminish their viability in a time- and dose-
dependent manner by inducing apoptosis evident from
morphological studies and TUNEL assay. Protein profiling by
western blot revealed an elevated BAX to Bcl-2 ratio which
leads to apoptosis by caspase-3 activation and PARP
cleavage. In addition, a prominent increase in apoptosis-
inducing factor and decrease in XIAP levels was observed.
Thus, a caspase-dependent apoptotic cell death can be
inferred. It exerted moderate effect on normal cells, HaCat,
HBL-100 and NIH/3T3. In addition, at a sub-lethal dose, a
marked reduction in chemoinvasive and migratory potential
and prominently diminished angiogenesis both in vitro and
in vivo was observed. On detailed analysis of the cellular
pathways, we understood that EP4 blockade by GW627368X
reduced PKA phosphorylation, which in turn lead to
decreased CREB activation. This decreased PKA phosphor-
ylation is directly responsible for enhanced Bax activity and in
part reduces GSK3β phosphorylation. A decreased CREB
transcriptional activity restricts the aberrant transcription of
key genes like EP4, COX-2 and VEGFwhich ultimately control
cell survival, proliferation and angiogenesis.
Owing to the interactive signaling between EP4 and EGFR,
the phosphorylation status of downstream effectors like Akt,
MAPK and GSK3β are also affected, which play important role
in survival and proliferation (Supplementary Figure S1). We
also confirmed the transactivation of EGFR by EP4 and the
effect of GW627368X there in by exogenous overexpression
of PGE2. PGE2 stimulated EP4 receptor which in turn
significantly increased phosphorylation level of EGFR. Treat-
ment with GW627368X, however, lowered EGFR phosphor-
Figure 4 Anti-angiogenic potential of GW627368X. Cyclo-oxygenase/PGE2 axis is known to have prominent role in angiogenesis. (a) Western blot analysis of major players
of COX-PGE2 axis in cervical cancer cell lines treated with GW627368X (9, 10 and 10 μM for Hela, SiHa and ME 180, respectively) for different time points and control treated
with 0.1% DMSO. (b) Quantification of protein expression by densitometry, normalized against β-actin, each representative of three different experiments performed in triplicates,
values presented as mean± S.D.; *Po0.05, **Po0.01, ***Po0.001. (c) Quantitative analysis of the PGE2 concentration in conditioned media of GW627368X treated cells (9,
10 and 10 μM for Hela, SiHa and ME 180, respectively), stimulated or unstimulated by 10 μM arachidonic acid by ELISA. Graphs representative of three different experiments
each performed in triplicates, values presented as mean±S.D.; Po0.05, **Po0.01, ***Po0.001. (d) Quantitative estimation of the secretory VEGF concentration in
conditioned media of GW627368X treated cells (9, 10 and 10 μM for Hela, SiHa and ME 180 respectively) by ELISA. Graphs representative of three different experiments each
performed in triplicates, values mean±S.D.; Po0.05, **Po0.01, ***Po0.001. (e and f) In vitro tube formation assay. (e) HUVECs were seeded (7.5 × 103 cells/well) into a 96-
well tissue culture plate coated with 50 μl matrigel; VEGF (25 ng/ml), GW627368X (IC50 for 48 h/3)or both were added and incubated in HUVEC growth medium in 37 °C, 5%
CO2 incubator. Tube formation was observed for 24 h and images were taken at × 10 magnification (f) Number of capillary-like structure formed by HUVECs in each condition was
counted under light microscope after 24 h in four independent experiments. Data presented as mean± S.D., Po0.05, **Po0.01, ***Po0.001. (g and h) Chorioallantoic
membrane (CAM) assays. (g) Photomicrographs representing developing chick embryos implanted with sterile filter disks loaded with serum-free media as control and serum-
free media supplemented with VEGF (25 ng/ml), GW627368X (IC50 for 48 h/3) or both to observe the angiogenic response (h) The number of blood vessels formed in each test
group was counted under stereo microscope and plotted to evaluate the extent of angiogenic response. Data presented as mean± S.D., Po0.05, **Po0.01, ***Po0.001 of
three independent experiments performed in triplicates
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ylation in all cell lines. Inhibition of EGFR phosphorylation by
GW627368X in turn reduced the phosphorylation level of Akt,
MAPK and GSK3β significantly. β-catenin is an important
transcription factor whose activity is controlled by Akt and
GSK3β.20 On treatment with a sublethal dose, GW627368X
was found to reduce the nuclear translocation of β-catenin in a
time-dependent manner. In addition, we also observed a time-
dependent decrease in cytoplasmic as well as cellular
β-catenin. TCF-β-catenin activation is known to be associated
with activation of variety of genes-like c-myc and cyclin D1.20
EGFR activation leads to an increased activator protein-1-
mediated induction of COX-2 transcription via MAPK and
enhanced synthesis of PGE2.12 Reduced 15-hydro-
xyprostaglandin dehydrogenase expression restricts PGE2
catabolism resulting in enhanced accumulation of PGE2 in
the tumor vicinity.11 This explains the reduced PGE2 and VEGF
secretion we observed in respective immunoassays and can be
implicated in hindered angiogenesis.
As discussed earlier, EP4 transactivates and interacts with
EGFR via multiple context specific pathways. Being a
competitive EP4 antagonist, GW627368X prevents ligand
receptor interaction when ambient PGE2 level is increased by
exogenous addition. This in turn restricts EGFR transactiva-
tion and corresponding downstream pathways which explains
the downregulation of pMAPK, pAkt and pGSK3β along with
pEGFR. Disruption of cross talk between receptors is also
validated by a similar downregulation of the effectors on
blocking EGFR using mAb with or without the drug. Disruption
of this cooperative signaling leads to reduced activity of
transcription factors CREB and β-catenin resulting in reduced
synthesis of survival factors. In xenograft model, a dose-
dependent decrease in proliferating cancer was evident from
Figure 5 GW627368X interferes with EP4/EGFR interactive signaling in cervical cancer. (a–d) Cervical cancer cells were treated with 9, 10 and 10 μM of drug for HeLa, SiHa
and ME 180, respectively, followed by stimulation with 25 ng/ml of recombinant EGF for 30 min and equal amount of proteins (50 μg) were analyzed by western blotting. (a)
Representative blots showing western blot analysis of key proteins. (b–d) Relative levels of phosphorylation of each protein was determined by densitometry. Data presented as
mean± S.D., Po0.05, **Po0.01, ***Po0.001 of three independent experiments performed in triplicates. (e) Cells were treated with one third of IC50(48 h) of the drug,
incubated for different time periods and protein was extracted from whole cell, nuclear and cytoplasmic fractions and relative β-catenin expression in equal amount of protein
(50 μg) was analyzed by western blot. (f and g) The relative levels of protein expression was determined by densitometry. Data presented as mean± S.D., Po0.05, **Po0.01,
***Po0.001 of three independent experiments performed in triplicates
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Figure 6 Hindrance of EP4/EGFR cross-talk validated by exogenous overexpression of PGE2 and EGFR blockade. (a and b) Cells were stimulated with exogenous PGE2
(100 nM) and phosphorylation status of stimulated or unstimulated cells with or without drug treatment was studied by western blot. (a) Representative blots showing
phosphorylation levels of EGFR in cervical cancer cell lines. (b) The relative levels of pEGFR expression was determined by densitometry. Data presented as mean± S.D.,
Po0.05, **Po0.01, ***Po0.001 of three independent experiments performed in triplicates. (c–h) Cells were stimulated with exogenous PGE2 (100 nM) and EP4, EGFR or
both were blocked with GW627368X9 (9, 10 and 10 μM of drug for HeLa, SiHa and ME 180), EGFR mAb (20 ng/ml) or both and phosphorylation status of key downstream
molecules were studied by western blot. (c, e and g) Representative blots showing activation levels of key regulator proteins in ME 180, HeLa and SiHa, respectively. (d, f and h)
The relative levels of protein expression was determined by densitometry. Data presented as mean±S.D., Po0.05, **Po0.01, ***Po0.001 of three independent experiments
performed in triplicates
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dose-dependent reduction in tumor mass and volume and a
marked decrease in Ki67 expression. A diminished CD31
specific staining signified decreased tumor angiogenesis.
Reduced expression of pAkt, pMAPK, pEGFR and COX-2
confirmed our in vitro results.
It can therefore be inferred from our in vitro and in vivo
results that GW627368X effectively diminishes tumor survival,
motility, proliferation and angiogenesis by blocking EP4/EGFR
interactive signaling in cervical cancer. Our results demon-
strate EP4 as a potent therapeutic target in cervical cancer
and can be effective in combination with conventional
therapies to attain superior outcomes and to overcome
complications associated with organ toxicities, therapeutic
resistance and disease relapse.
Materials and Methods
Cell lines. Cervical cancer cells HeLa, SiHa and ME 180 were procured from
National Centre for Cell Science (Pune, India) and maintained in 5% CO2
atmosphere, at 37 °C and 95% humidity in DMEM (Gibco-BRL, Rockville, MD, USA;
HeLa and SiHa) and McCoy-5A (Sigma Aldrich, St. Louis, MO, USA; ME 180)
supplemented with 10% heat inactivated FBS (Gibco-BRL)
Reagents. GW627368X (Cayman Chemical Item Number 10009162, CAS
439288-66-1) and CJ-023423 (Cayman Chemical Item number 10010355, CAS
415903-37-6) were procured from Cayman chemicals, Ann Arbor, MI, USA, made
into stock solutions of 10 mM in DMSO and stored at − 20 °C, diluted into fresh
medium before use. For western blot and IHC rabbit monoclonal anti-COX-2, anti-
apoptosis-inducing factor, anti-BAX, anti-Bcl-2, anti-vascular endothelial growth
factor receptor, anti-p-vascular endothelial growth factor receptor, anti-EGFR,
anti-p-EGFR, anti-Akt, anti-p-Akt, anti-MAPK, anti-p-MAPK, anti-Ki67, anti-Ras,
anti-p-Ras, anti-Raf, anti-p-Raf, anti-GSK3β, anti-p-GSK3β, anti-βCatenin, anti-p-
βCatenin, anti-CD31(Cell Signaling Technology, Beverly, MA, USA), mouse
monoclonal anti-β-actin (Cell Signaling Technology) and goat monoclonal anti-
EP4 (Imgenex, Bhuvaneswar, India), horseradish peroxidase conjugated goat anti-
rabbit immunoglobulin G and goat anti-mouse immunoglobulin G (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), Chemiluminescent peroxidase substrate,
propidium iodide and MTT (Sigma Aldrich) ApopTag In Situ Apoptosis detection kit
(Promega, Madison, WI, USA), Rhodamine phallaoidin (Invitrogen Corporation, CA,
USA) Fetal bovine serum (FBS) (Gibco-BRL, Invitrogen Corporation, CA, USA),
PGE2 immunoassay kit (Imgenex, India), Human VEGF quantikine ELISA kit (R&D
systems, Minneapolis, MN, USA), and IHC detection system (Biogenex, Fremont,
CA, USA) were purchased from corresponding companies. Stock solutions of
propidium iodide and MTT were prepared by dissolving 1 mg of each compound in
1 ml phosphate-buffered saline. The solutions were stored in dark at 4 °C and used
within 1 month. Stock concentrations of 10 mg/ml RNase A (Sigma Aldrich) was
prepared and kept at − 20 °C.
Figure 7 Validation of the effect of EP4 inhibition in cervical cancer using CJ-023423, a highly selective EP4 inhibitor as positive control. (a) Dose-dependent inhibitory effect
of CJ-023423 on growth of cervical cancer cell line, ME 180. ME 180 cells were treated with various concentrations of GW627368X for 48 h. Points, average±S.D.,
representative of three independent experiments each performed in triplicates, Po 0.05. (b and c) ME 180 cells were treated with GW627368X (10 μM) and CJ-023423(7 μM)
followed by stimulation with EGF. The relative phosphorylation levels of important signaling mediators were studied by western blot analysis. (b) Representative blots showing
western blot analysis of key proteins. (c) The relative levels of phosphorylation of each protein was determined by densitometry. Data presented as mean±S.D., Po0.05,
**Po0.01, ***Po0.001 of three independent experiments performed in triplicates
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Cell viability assay. Cell proliferation was determined by traditional MTTassay
with slight modification and LIVE/DEAD assay.21 Cell viability was measured by
MTT dye reduction assay at 24 and 48 h after GW627368X treatment(0-100 μM) at
540 nm.22 The time dependent dose-response curves were analyzed using Prism
software (GraphPad Prism, CA, USA). LIVE/DEAD assay was performed in drug
treated cells (9,10 and 10 μM for HeLa, SiHa and ME 180 respectively) for 12, 24
and 48 h using LIVE/DEAD Viability/Cytotoxicity kit (Life Technologies, Carlsbad,
CA, USA) as per the manufacturer’s instructions.21 The percentages of live and
dead cells were calculated and plotted using Prism software (GraphPad Prism,
CA, USA).
Cell cycle analysis. Cells grown to 70-80% confluence were treated with
GW627368X (9, 10, 10 μM for HeLa, SiHa and ME 180 respectively) for varying
time points, 70% ethanol fixed, RNaseA (100 μg/ml) and propidium iodide at a final
concentration of 40 μg/ml added and incubated for 45 min at 37 °C. Cells were
analyzed with FACS Vantage SE (BD Corporation, Franklin Lakes, NJ, USA).
Results obtained were analyzed with Cell Quest software version 2.0 (BD).
TUNEL assay. Occurrence of apoptosis was investigated by TUNEL assay on
cells treated with 9, 10, 10 μM GW627368X for HeLa, SiHa and ME 180
respectively for 0, 24 and 48 h and on tissue sections of excised tumors using
ApopTag Peroxidase in situ Apoptosis Detection Kit (Promega) following kit
protocol.23 Cells were analyzed by confocal laser scanning microscope at × 20
magnification.
Morphological studies. Adherent monolayer cells were washed with phosphate-
buffered saline, fixed with 4% paraformaldehyde and permeabilized with 0.1% triton
X-100 for 1 min. Rhodamine phalloidin staining was performed to visualize cell
cytoskeleton while DAPI was used to stain nuclei.23 Fluorescent images were captured
under a Zeiss Observer Z1 microscope (Carl Zeiss, Germany) at × 20 magnification.
Wound-healing assay. Monolayers of HeLa, SiHa and ME 180 were
wounded using a pipette tip, cultured in presence or absence of GW627368X
(IC50/3) for different time points till 48 h and cells invading the wound line were
observed under an inverted phase-contrast microscope using × 10, Leica DMR,
Germany. Wounds were quantified from distance between edges using Leica QWin
software, Richmond, IL, USA.22
Boyden chamber invasion assay. Filters (8 μm) coated with Matrigel
(20 μg/ filter) were placed in Boyden chambers. ME 180 cells (1 × 105), suspended
in DMEM containing 0.1% BSA and treated with GW627368X, were placed on the
top chamber. Conditioned medium from NIH/3T3 mouse fibroblast cells was used as
chemoattractant source and placed in the bottom compartment. Following 24 h
incubation at 37 °C, non-invading cells were scraped off, and cells migrated to lower
surface of filter inserts were fixed using 100% methanol for 10 min and stained with
haematoxylin.21 Results are expressed as percent of migrated cells as compared
with control.
Chick chorioallantoic membrane assay. Fertilized eggs were incubated
at 37 °C in 60–70% relative humidity for 7 days after which 1–2 cm2 windows were
opened and sterile round filter paper disks (5 mm in diameter, Whatman qualitative
Figure 8 GW627368X hinders tumor progression in vivo. Subcutaneous tumor-bearing nude mice were treated with GW627368X orally ranging from 0 to 10 mg/Kg body
weight, thrice a week, for 4 weeks. (a) Representative picture showing subcutaneous tumor (ME 180)-bearing nude mice of different treatment groups. (b) Representative picture
showing excised tumors from corresponding treatment groups of ME 180 xenografts. (c) Graph representing change in tumor volume (group average; ME 180 xenografts) in each
test group measured every week. Data presented as mean±S.D. (n= 5), P= 0.0125. (d) Representative picture showing tumors excised from different treatment groups of SiHa
xenografts. (e) Graph representing change in tumor volume (group average; SiHa xenografts) in each test group measured every week. Data presented as mean± S.D. (n= 5),
P= 0.0002. Paraffin-embedded excised tumors from different treatment groups of ME 180 xenografts were sectioned, processed and (f) In situ TUNEL assay to assess induction
of apoptosis within tumor and IHC specific for COX-2, Ki67(proliferation marker) and CD31(anigiogenesis marker) were performed (g) Photomicrographs representing IHC
performed for specific signaling proteins, pMAPK, MAPK, pAkt, Akt, pEGFR and EGFR
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filter papers, Sigma-Aldrich, St. Louis, MO, USA) containing serum-free medium
alone as control, VEGF (25 ng/ml), GW627368X or both (one third of IC50) was
applied onto chorioallantoic membrane of individual embryos. After 2 days
incubation, upper eggshell was removed and capillaries within 2.5 mm around the
filter paper were observed and photographed under a stereomicroscope22
(Olympus, SZX16, Center Valley, PA, USA).
HUVEC assay. Growth factor-depleted matrigel was applied to a 96-well tissue
culture plate (50 μl per well). After polymerization(37 °C, 1 h), HUVECs, serum
starved for 2 h were harvested, washed with assay medium and 7.5 × 103 cells/well
(final volume, 50 μl) were seeded on polymerized matrigel without or with
drug(IC50/3), VEGF(25ng/ml) or both. The plate was incubated at 37 °C for 24 h,
medium was aspirated and cells fixed in neutral buffered 10% formalin.21
Representative pictures were taken at × 10 magnification.
Protein isolation and western blotting. Cervical cancer cells HeLa, SiHa
and ME 180 were grown and treated with 9, 10 and 10 μM GW627368X,
respectively, for 12, 24 and 48 h or with 0.1% DMSO in cell culture dishes for 48 h.
For phosphorylation studies, experimental plates were treated with same dose of
GW627368X, whereas control plates were treated with 0.1% DMSO for 1 h. The
cells were then stimulated with recombinant human EGF (25 ng/ml) for 30 min. The
cells were scraped and lysed in Nonidet P-40 lysis buffer. Cell lysate containing
50 μg protein was separated on sodium dodecyl sulfate–polyacrylamide electro-
phoretic gel, transferred to nitrocellulose membranes followed by blocking in 3%
BSA for 2 h. The membranes were then incubated with primary antibodies overnight
at 4 °C and then with horseradish peroxidase-conjugated secondary antibody for
2 h at room temperature.22 Proteins were visualized using chemiluminescence
substrate and exposed to Kodak X-OMATAR autoradiography film (Eastman Kodak,
Rochester, NY, USA).
To validate the signaling mechanism involved, phosphorylation status of different
protein molecules were studied after either stimulating or blocking the key receptors.
In brief, overnight serum starved cells were stimulated with 100 nM PGE2
exogenously. Prostanoid receptor EP4 was blocked using GW627368X whereas
EGFR was blocked using 20 ng/ml EGFR monoclonal blocking antibody. Relative
activity of downstream regulators was studied by western blot after blocking or
stimulating either of the receptors or in combination.
Sub-cellular fractionation. Sub-cellular fractionation was performed as earlier
reported with minor modification and western blotting was performed.24 Cells were
washed with cold phosphate-buffered saline and pellet collected by centrifugation at
3000 r.p.m. for 10 min. Cells were incubated on ice for 15 min in hypotonic buffer A and
homogenized. Nuclei were separated from the cytosolic fraction by centrifugation at
5000 r.p.m. for 5 min at 4 ºC. Cytosolic fraction was centrifuged at 40 000 r.p.m. for
30 min to pellet the crude membranes. Nuclei were washed and resuspended in
nuclear protein extraction buffer,24 lysed with vigorous shaking for 20 min and
centrifuged at 15 000 r.p.m. for 30 min to collect the soluble nuclear fraction.
PGE2 and VEGF quantification by ELISA. For quantification of PGE2,
cells were allowed to grow for 24 h and treated with 9, 10 and 10 μM GW627368X
for HeLa, SiHa and ME 180, respectively, in serum-free medium for 1 h followed by
stimulation of the cells with 10 μM arachidonic acid. After an incubation period of
24 h, PGE2 concentration in conditioned media was quantified using IMGENEX
PGE2 EIA kit as per manufacturer’s protocol. For VEGF quantification, cells were
grown for 24 h and treated with same drug dosage or 0.01% DMSO and incubated
for 24 h. To maintain stability of VEGF, treatment was carried out in medium
supplemented with 2% FBS. VEGF concentration in conditioned medium was then
measured using VEGF quantikine ELISA kit, R&D according to kit protocol.25
Tumor xenograft. Female athymic nude mice (N:NIH(S)) purchased from
National Institute of Nutrition, Hyderabad, India were housed in National Institute of
Cholera and Enteric Diseases, Kolkata, India in accordance with institutional
guidelines. Experiments were approved by Institutional Animal Ethical Committee
and were conducted observing all Animal Ethics Regulation streamlined by the
Institutional Animal Ethics Committee concerned under guidance of the Committee
for the purpose of Control and Supervision of Experiments on Animals, Govt. of
India. Animals were allowed free access to standard laboratory rodent food and
water under good laboratory conditions (temperature 25± 2 °C; relative humidity
50± 20%) with dark and light cycle (12/12 h). Mice (6–8-week-old) having body
weight around 20–22 g were used for experiment. Exponentially growing ME 180/
SiHa cells were harvested and a tumorigenic dose of 2.5 × 107 cells in matrigel
0.5 mg/ml was injected subcutaneously in flanks of the mice.23 After ME 180 tumors
attained a volume of about 100mm3, mice were randomized into five groups of five
mice per group. In case of SiHa xenograft, as there was very poor tumor formation,
an initial volume of only about 10 mm3 could be attained. Groups of animals were
treated with varying doses of drugs (i) control; (ii) 2 mg/kg; (iii) 4 mg/kg; (iv) 6 mg/
kg; and (v) 10 mg/kg. Treatment was administered for a period of 4 weeks (3 times
a week) using an oral gavage. Tumor volume was measured twice a week by a side
callipers, using equation: V= (A) (B2)π /6, where A was the length of longest aspect
of tumor, and B was the length of tumor perpendicular to A.21
Immunohistochemistry. Tumor specimen excised from respective groups of
ME 180 xenografts were fixed in 10% formalin, embedded in paraffin and sectioned.
For immunohistochemical analysis, tissue sections were deparafinized followed by
antigen retrieval. IHC for specific proteins were carried out on tumor tissue sections
using Biogenex IHC detection system according to manufacturer’s guidelines with
different antibodies including anti–pAkt, anti–Akt, anti–Ki67, anti–CD31, anti–
pEGFR, anti-EGFR, anti-pMAPK, anti-MAPK and anti-COX-2 proteins.
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